The Effects of Caffeine on Physical Performance of Ice Hockey Players (cafhoc)

May 23, 2023 updated by: Alejandro Gómez Bruton, Universidad de Zaragoza

The Effects of Caffeine on Physical Performance of Ice Hockey Players: A Cross-over Randomized Controlled Trial

To date, only one study has evaluated the effect of caffeine supplementation on athletic performance in ice hockey players finding a lack of ergogenic effect. This lack of effect is surprising as caffeine has been suggested to be an effective and safe nutritional supplement to improve physical performance in both trained and untrained individuals. Therefore, the aim of the present study is to evaluate the effect of acute caffeine ingestion (3mg/kg body mass). Thirteen elite adult ice-hockey male players will perform specific ice hockey performance tests in two separate days. On both occasions players will ingest 330 ml of water with lemon powertabs isostar® (86 kcal / 19g of carbohydrates) tablets, which will include in one of these days 3 mg/kg body mass of anhydrous caffeine. Players will perform a 35-m sprint, an agility test (Weave agility - slalom with puck), and a reaction test.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Zaragoza, Spain, 50012
        • Universidad de Zaragoza

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Over 18 years,
  • Male
  • Play in the Spanish ice hockey first division.

Exclusion Criteria:

  • Participants taking drugs containing ephedrine or antibiotics.
  • Having suffered a musculoskeletal injury in the 3 months prior to the tests.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Caffeine
Dietary Supplement: Caffeine supplementation Participants will ingest caffeine in liquid form (3mg/kg) with carbohydrates.
Dietary supplement: Caffeine
Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
Placebo Comparator: Control condition
Participants will ingest a drink of carbohydrates without caffeine
Dietary supplement: Placebo drink
Participants will ingest the exact same drink without caffeine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
35m sprint time (Seconds)
Time Frame: One day (one hour post caffeine consumption)
Time that participants take to skate 35 meters. Data will be collected with photoelectric cells
One day (one hour post caffeine consumption)
Agility test time (Seconds)
Time Frame: One day (one hour post caffeine consumption)
Time that participants take to perform an agility circuit. Data will be collected with photoelectric cells
One day (one hour post caffeine consumption)
Reaction test time (seconds)
Time Frame: One day (one hour post caffeine consumption)
Time that participants take to complete a reaction test circuit. Data will be collected with photoelectric cells.
One day (one hour post caffeine consumption)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universidad de Zaragoza

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2021

Primary Completion (Actual)

April 30, 2021

Study Completion (Actual)

May 30, 2021

Study Registration Dates

First Submitted

December 9, 2021

First Submitted That Met QC Criteria

December 9, 2021

First Posted (Actual)

December 27, 2021

Study Record Updates

Last Update Posted (Actual)

May 24, 2023

Last Update Submitted That Met QC Criteria

May 23, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Caffeinehockey

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Athletic Performance

Clinical Trials on Caffeine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe